yehM Antibody

What is the significance of Yeh's antibody development approach compared to traditional methods?

Professor Yeh's laboratory employs biomolecular engineering approaches to develop antibodies, which differs from traditional methods in several key aspects. Their work focuses on dissecting signal transduction pathways and targeting specific protein functions . Unlike conventional approaches that primarily rely on affinity-based selection, the Yeh lab integrates function-based screening with innovative display technologies.

This approach has resulted in several therapeutic inhibitors targeting oncogenic receptors, transcription factors, and extracellular matrix proteins. Most notably, their research has led to the development of therapeutic biologics that modulate the interplay between cancer cells and the tumor microenvironment .

Methodological comparison:

How do researchers validate antibody specificity in experimental designs?

Antibody validation is a critical step that ensures experimental reliability. Based on current research practices, validation typically involves:

• Western blot analysis - As demonstrated with the anti-Histone H4 (acetyl K8) antibody, bands of predicted sizes (11 kDa) confirm target specificity .

• Positive and negative controls - Using known positive samples (e.g., HT-29 human colon adenocarcinoma cells) versus negative samples (e.g., Daudi human Burkitt's lymphoma cells) for EpCAM/TROP-1 antibody validation .

• Treatment validation - Testing antibody response in treated versus untreated samples, as shown with Trichostatin A treatment for Histone H4 acetylation studies .

• Multiple techniques cross-validation - Using different methods (Western blot, immunoprecipitation, immunohistochemistry, flow cytometry) to confirm consistent target detection .

• Knockout/knockdown controls - While not directly mentioned in the search results, this is a gold standard approach to confirm specificity.

How can immune checkpoint modulation enhance antibody induction in HIV-1 vaccine development?

Research has demonstrated that modulation of specific immune checkpoints can significantly enhance HIV-1 antibody responses. According to the study by Yeh et al., targeting immune cell regulatory receptors CTLA-4, PD-1, or OX40 alongside HIV envelope (Env) vaccines produces measurable enhancements:

• CTLA-4 blockade augments HIV-1 Env antibody responses in macaques .

• In bnAb-precursor mouse models, CTLA-4 blocking or OX40 agonist antibodies increase germinal center B cells and T follicular helper cells, resulting in enhanced plasma neutralizing antibodies .

The mechanism involves promoting germinal center activity, which is critical for antibody affinity maturation and the development of broadly neutralizing antibodies (bnAbs). This approach represents a potential breakthrough for HIV-1 vaccine development, which has historically struggled to induce protective titers of bnAbs in humans .

What methodologies are employed in high-throughput discovery of agonist antibodies?

The discovery of agonist antibodies, particularly those that activate rather than inhibit cellular signaling, requires specialized approaches. Current methodologies include:

• Autocrine function-based screening systems:

  • Surface-displayed antibody libraries are expressed on mammalian reporter cells

  • Each cell expresses a single antibody that can interact with target receptors

  • Positive clones are isolated based on reporter activation

  • Approach reduces stringency for antibody affinity, helping identify rare clones with desirable biological properties

• Phage display followed by functional screening:

  • Initial enrichment for binders using phage display

  • Subsequent function-based screening in mammalian reporter cells

  • Multiple rounds of activity-based sorting with culturing between rounds

  • Single-cell sorting, expansion, and functional evaluation

• Co-encapsulation systems:

  • Primary B cells and reporter cells co-encapsulated in agarose-based microdroplets

  • Isolation based on fluorescence patterns reporting antigen binding and cellular responses

  • Paracrine-like selection systems combining phage-producing bacteria with mammalian reporter cells

These methodologies have been successful in identifying antibodies with desired agonist functions, overcoming the traditional hurdle of primarily discovering antagonistic antibodies.

How do anti-MOG antibody serologies correlate with clinical outcomes in demyelinating diseases?

Anti-Myelin Oligodendrocyte Glycoprotein (MOG) antibodies have significant implications for demyelinating disease diagnosis and treatment decisions. Based on prospective cohort studies:

• Approximately one-third of children with incident demyelination are positive for anti-MOG antibodies .

• Clinical presentations typically include a combination of optic neuritis, transverse myelitis, and acute disseminated encephalomyelitis in 96% of anti-MOG antibody-positive children .

• On serial serum analysis, 57% of participants (38 of 67) who were seropositive at onset became seronegative, with a median time to conversion of 1 year .

• Relapse patterns differ significantly based on antibody persistence:

  • Clinical relapses occurred in 38% of children (9 of 24) who remained persistently seropositive

  • Only 13% of children (5 of 38) who converted to seronegative status experienced relapses

• Most anti-MOG antibody-positive children experience a monophasic disease course, suggesting that the presence of anti-MOG antibodies at initial demyelination should not immediately prompt long-term immunomodulatory therapy .

These findings have important implications for treatment decisions and prognostication in pediatric-onset demyelinating disorders.

What is the role of bispecific antibodies in multiple myeloma treatment?

Bispecific antibodies represent a promising therapeutic approach for multiple myeloma (MM), particularly for patients with relapsed/refractory disease. Key research findings include:

• Bispecific molecules, including bispecific antibodies (BisAbs) and bispecific T-cell engagers (BiTEs), promote immune-mediated lysis of MM cells by simultaneously binding antigens on MM cells and immune effector cells .

• BisAbs targeting B-cell maturation antigen (BCMA) and GPRC5D have demonstrated impressive clinical activity in early trials .

• Early-phase clinical trials targeting FcRH5 in patients with relapsed/refractory MM (RRMM) also show promising results .

• These agents exhibit favorable safety profiles, primarily causing low-grade cytokine release syndrome (CRS) .

The mechanism of action involves bringing immune effector cells into proximity with MM cells, enhancing immune recognition and cytotoxicity. As "off-the-shelf" therapeutics, these bispecific molecules may become an essential component of MM treatment paradigms, potentially leading toward curative approaches when combined with standard-of-care treatments .

How should experiments be designed to accurately evaluate antibody sensitivity over time?

When designing experiments to evaluate antibody sensitivity over time, researchers should consider several critical factors based on established studies:

• Appropriate time stratification:

  • Analysis should stratify results by time since symptom onset or exposure

  • Data pooled across different time periods post-symptom onset show substantial heterogeneity (range 0% to 100% for IgA, IgM, and IgG antibodies)

  • Weekly intervals are commonly used for initial evaluation periods

• Sample size considerations:

  • Small sample sizes within each time interval reduce reliability

  • Studies should be designed with sufficient participants at each time point

  • Tracking the same groups of patients over time provides more reliable data than cross-sectional sampling

• Antibody class evaluation:

  • Test multiple antibody classes (IgA, IgM, IgG) or combinations

  • Different antibody classes show distinct temporal sensitivity patterns:

    • IgG/IgM sensitivity: 30.1% (1-7 days), 72.2% (8-14 days), 91.4% (15-21 days), 96.0% (21-35 days)

  • Beyond 35 days, insufficient studies exist to reliably estimate sensitivity

• Control implementation:

  • Include appropriate negative and positive controls

  • Assess specificity with diverse control samples (>98% specificity is achievable)

• Population diversity:

  • Include both hospitalized and non-hospitalized subjects

  • Consider disease severity spectrum (mild, moderate, severe)

  • Account for asymptomatic cases when applicable

What are the critical factors in designing FACS-based antibody discovery experiments?

Fluorescence-activated cell sorting (FACS) is a powerful tool for antibody discovery. Based on current research approaches, the following factors are critical for experimental design:

• Library preparation and display format:

  • Surface-displayed antibody libraries should be optimized for expression

  • Each cell should express a single antibody variant

  • Consider lentiviral transduction for stable integration of antibody genes

• Reporter system design:

  • Reporter cells should provide clear signal-to-noise differentiation

  • Consider fluorescent proteins or selectable phenotypes for isolation

  • Ensure reporter activation correlates with desired antibody function

• Sorting strategy:

  • Multiple rounds of sorting with expansion between rounds improves enrichment

  • Single-cell sorting into individual wells enables clonal expansion and evaluation

  • Balance stringency to avoid losing rare clones with desirable properties

• Co-culture considerations:

  • For complex functional screens, co-encapsulation of cells in microdroplets enables paracrine interactions

  • Ensure viability of mammalian cells when co-cultured with other cell types (e.g., bacteria)

  • Droplet stability in aqueous phase is critical for FACS-based screening

• Recovery and validation:

  • Optimize genomic DNA recovery from isolated cells

  • Use next-generation sequencing for comprehensive sequence identification

  • Validate candidate antibodies in soluble format for biological activity and biophysical properties

How can researchers evaluate the epitope specificity of therapeutic antibodies?

Epitope specificity is crucial for understanding antibody function and therapeutic potential. Based on research approaches, epitope evaluation can be conducted through:

• Structural analysis using cryo-electron microscopy:

  • Single-particle analysis can reveal binding interfaces

  • This approach was used to show that antibody O5C2 targets a large epitope within the receptor-binding domain of SARS-CoV-2 spike protein that overlaps with the ACE2 binding interface

• Competition assays:

  • Testing whether antibodies compete with natural ligands provides insight into binding sites

  • For example, competition analysis showed that one antibody (V-2) was competitive with EPO binding, while another (V-1) bound EpoR at a non-overlapping epitope

• Epitope mapping techniques:

  • Peptide arrays or alanine scanning mutagenesis

  • Domain swapping or chimeric constructs

  • Hydrogen-deuterium exchange mass spectrometry (HDX-MS)

• Functional evaluation:

  • Correlating epitope binding with functional outcomes

  • For instance, biepitopic antibodies targeting non-overlapping epitopes can induce receptor clustering and activation

What approaches can resolve contradictory antibody test results in research settings?

When faced with contradictory antibody test results, researchers can employ several methodological approaches to resolve discrepancies:

• Multiple testing methodologies:

  • Use different antibody detection platforms (ELISA, lateral flow, chemiluminescence)

  • Compare results across different testing formats to identify platform-specific biases

• Temporal considerations:

  • Account for time-dependent sensitivity variations

  • Re-test samples at appropriate intervals to capture antibody kinetics

  • Consider antibody waning in longitudinal studies

• Isotype-specific analysis:

  • Test for multiple antibody isotypes (IgG, IgM, IgA)

  • Different isotypes have different kinetics and potential for cross-reactivity

• Statistical approaches:

  • Employ Bayesian methods to incorporate prior probabilities

  • Use latent class analysis when no perfect reference standard exists

  • Meta-analytical approaches to integrate multiple test results

• Validation with orthogonal methods:

  • Confirm antibody binding with functional assays (neutralization)

  • Use cell-based assays to complement protein-binding assays

  • Employ epitope-specific confirmatory tests

How might the work from Yeh's laboratory impact future cancer therapeutics development?

Based on the current trajectory of research from Yeh's laboratory and related fields, several promising directions for cancer therapeutics are emerging:

• Targeting the tumor microenvironment:

  • The Yeh lab is focused on developing therapeutic biologics to modulate the interplay between cancer cells and the tumor microenvironment .

  • This approach recognizes cancer as an ecosystem rather than focusing solely on cancer cells.

• Antibody-dependent cell-mediated cytotoxicity (ADCC):

  • Research on broadly neutralizing antibodies with ADCC activities suggests potential for dual-mechanism therapeutics .

  • These antibodies can directly neutralize targets while also recruiting immune effector functions.

• Anti-GFRAL antibody applications:

  • Professor Yeh's work on anti-GFRAL human antibodies for alleviating chemotherapy-induced cancer cachexia represents an important supportive care approach .

  • This could improve quality of life for cancer patients while enhancing their response to continuous anti-cancer therapy.

• Bispecific antibody development:

  • The potential of bispecific antibodies to engage immune cells against cancer cells is being explored in multiple myeloma and potentially other cancers .

  • This approach could be extended to solid tumors based on appropriate target selection.

• Function-based antibody discovery:

  • The shift from purely affinity-based to function-based antibody discovery methods may yield therapeutics with novel mechanisms of action .

  • This could address currently undruggable targets in cancer signaling pathways.

What are the methodological challenges in developing agonist antibodies for clinical applications?

Developing agonist antibodies for clinical applications presents several unique methodological challenges compared to antagonist antibodies:

• Functional screening requirements:

  • Traditional affinity-based selection is insufficient; function-based screening is essential

  • Many design principles for antagonists do not apply to agonists, requiring new discovery paradigms

  • High-throughput functional assays need to be developed for each target pathway

• Receptor clustering and multimerization:

  • Many receptors require clustering or higher-order organization for signaling

  • Engineering antibodies with appropriate valency and geometry is challenging

  • Biepitopic antibodies may be necessary but add complexity to development

• Dosing and pharmacology complexities:

  • Agonist antibodies often exhibit bell-shaped dose-response curves

  • Therapeutic window may be narrower than for antagonist antibodies

  • Predicting in vivo pharmacology from in vitro assays is particularly challenging

• Target-specific optimization:

  • Different signaling mechanisms (G-protein coupled receptors, receptor tyrosine kinases, etc.) require distinct optimization strategies

  • Some targets like GPCRs are difficult to raise antibodies against due to limited exposed extracellular regions

• Translational challenges:

  • Activity-modulating antibodies may show species-specific differences

  • Developing appropriate animal models that recapitulate human receptor signaling

  • Safety concerns related to potential off-target activation or excessive on-target stimulation